In conjunction with our previous report that TS5-p45 potently suppressed subcutaneous B16 melanoma growth in mice, our findings here signify that TS5-p45 could be further exploited as a cell surface NCL-targeted anti-cancer therapeutics in the future. The gene discussed is NUCLEOLIN; the disease is cancer.